Multidrug-resistant tuberculosis(MDR-TB) is a major problem in the prevention and treatment of tuberculosis worldwide, but the treatment success rate is low, and it is necessary to develop new anti-tuberculosis drugs and optimize treatment. Delamanid, a drug with good activity against MDR-TB, has been marketed in recent years. However, there is a lack of clinical medication guidance of delamanid for tuberculosis treatment. To standardize the rational application of delamanid in clinical practice, Chinese Tuberculosis Society organized experts in related fields to issue this consensus. This consensus described the molecular structure, anti-tuberculosis mechanism, pharmacodynamics/pharmacokinetics, drug resistance mechanism, and clinical research of delamanid, put forward recommendations for clinical application, and explained its suitable population, contraindications, methods of application, adverse events, and precautions, so as to provide a reference for clinicians to use delamanid.